Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

Perneger, Thomas; Brindel, Pauline; Combescure, Christophe; Gayet-Ageron, Angèle

doi:10.1016/j.jclinepi.2020.06.026

Article scientifique

Accès libre

Anglais

Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

Contributeurs/tricesPerneger, Thomas; Brindel, Pauline; Combescure, Christophe

; Gayet-Ageron, Angèle

Publié dansJournal of Clinical Epidemiology, vol. 127, p. 1-8

Date de publication2020

Résumé

The objective of the study is to estimate the proportion of statistically significant survival improvements reported in randomized trials of cancer treatments that are also compatible with a clinically negligible benefit.

Mots-clés

Confidence Intervals
Cross-Sectional Studies
Data Interpretation, Statistical
Humans
Neoplasms/drug therapy/mortality/radiotherapy
Periodicals as Topic/statistics & numerical data
Probability
Randomized Controlled Trials as Topic/statistics & numerical data
Treatment Outcome
Uncertainty

Structure d'affiliation

Groupe de recherche

Epidémiologie clinique et biostatistique (115)

Citation (format ISO)

PERNEGER, Thomas et al. Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments. In: Journal of Clinical Epidemiology, 2020, vol. 127, p. 1–8. doi: 10.1016/j.jclinepi.2020.06.026

Article (Published version)

CC BY-NC-ND

Identifiants

PID : unige:151658
DOI : 10.1016/j.jclinepi.2020.06.026
PMID : 32622900

ISSN du journal0895-4356

139vues

67téléchargements

Création03/05/2021 18:55:00

Première validation03/05/2021 18:55:00

Heure de mise à jour16/03/2023 00:34:37

Changement de statut16/03/2023 00:34:35

Dernière indexation12/02/2024 13:26:26

Archive ouverte UNIGE

Evidence of survival benefit was often ambiguous in randomized trials of cancer treatments

The objective of the study is to estimate the proportion of statistically significant survival improvements reported in randomized trials of cancer treatments that are also compatible with a clinically negligible benefit.

Informations techniques